Advertisement
Home »

Repigmentation Persists After Treatment Withdrawal from Topical Ruxolitinib

Mar 29, 2023

REFERENCES & ADDITIONAL READING

  1. Harris JE. Relapse and maintenance of clinical response in the randomized withdrawal arm of the TRuE-V long-term extension phase 3 study of ruxolitinib cream in vitiligo. S025, AAD Annual Meeting 2023, 17–21 March, New Orleans.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement